ReviewDrug design, development and therapy2025
Role of Radioiodine in Cancer Therapy: A Review of the Design and Challenges in Selecting Radioligands from Natural Sources.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of radioactive isotopes in cancer treatment has marked a pivotal shift in modern medicine, where precise diagnosis and targeted therapy now blend to offer patients more effective care with minimized side effects. Despite significant advancements, the exploration of iodine-labeled radioligands from natural sources remains underdeveloped, and comprehensive evaluations of their design, pharmacokinetics, and clinical relevance are still lacking. This gap has created a pressing need for systematic studies that bridge natural product chemistry with radiopharmaceutical applications. Since the initial application of iodine-131 in thyroid treatments, radioisotopes such as iodine-125 and iodine-131 have gained prominence in oncology due to their dual functionality: they enable accurate imaging while delivering therapeutic radiation directly to tumor cells, reducing harm to surrounding healthy tissues. Recent advancements in radiopharmaceuticals, particularly iodine-labeled compounds, aim to further improve this balance by enhancing cancer treatment efficacy and safety. This review synthesizes findings from clinical and experimental studies that explore a range of iodine-labeled compounds, including natural agents like hypericin, curcumin, and piperine, as well as various synthetic analogs. Key methodologies for incorporating iodine, such as the Iodogen method and other stable-labeling techniques, are evaluated for their impact on the compounds' pharmacokinetics, stability, and therapeutic performance. Furthermore, in silico methods are highlighted for their contribution to optimize the molecular structures, binding affinities, and specificity, streamlining the selection of high-potential candidates for radiopharmaceutical applications. Findings reveal that iodine-labeled compounds effectively concentrate in tumor cells, enhancing selectivity and reducing radiation exposure to non-cancerous tissues. Notably, these compounds demonstrate stability in biological environments, making them viable options for integrated diagnostic and therapeutic purposes. Moving forward, the ongoing refinement of compound stability and targeted biodistribution is crucial in ensuring these therapies can meet the demands of precision oncology and improve clinical outcomes across various cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.